Comprehensive Liver Investigation Workup
Begin with a thorough history focusing on alcohol consumption (>21 drinks/week men, >14 drinks/week women), metabolic risk factors (obesity, diabetes, hypertension, dyslipidemia), medication/herbal supplement use, and family history of liver disease, followed by physical examination for stigmata of chronic liver disease (spider angiomata, palmar erythema, ascites, splenomegaly), then proceed systematically through laboratory testing, non-invasive fibrosis assessment, imaging, and selective liver biopsy. 1
Step 1: Initial History & Physical Examination
Critical History Elements
- Alcohol intake: Quantify precisely in standard drinks per week over past 2 years; >50 units/week (men) or >35 units/week (women) significantly increases cirrhosis risk 2
- Metabolic factors: BMI >25, type 2 diabetes, dyslipidemia, hypertension (NAFLD/MASLD risk factors) 3
- Medications: All prescription drugs, over-the-counter medications, herbal supplements, particularly hepatotoxic agents (tamoxifen, amiodarone, methotrexate) 4
- Viral exposure: Blood transfusions, IV drug use, tattoos, sexual history, travel history 1
- Family history: Hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, autoimmune conditions 4
Physical Examination Findings
- Chronic liver disease stigmata: Spider angiomata, palmar erythema, gynecomastia, testicular atrophy, Dupuytren's contracture
- Portal hypertension: Splenomegaly, ascites, caput medusae, hepatic bruit (rare, only 1.7% of cases) 5
- Hepatic decompensation: Jaundice, asterixis (hepatic encephalopathy), muscle wasting 1
Step 2: First-Line Laboratory Testing
Essential Initial Labs 1, 2
- Liver enzymes: ALT, AST, alkaline phosphatase (ALP), GGT
- Hepatic function: Total and direct bilirubin, albumin, prothrombin time/INR
- Complete blood count: Platelets (thrombocytopenia suggests portal hypertension if <150,000/μL)
- Viral serology:
- Hepatitis B surface antigen (HBsAg)
- Hepatitis B core antibody (anti-HBc)
- Hepatitis C antibody (anti-HCV)
- HIV testing (all cases)
- Hepatitis A, E, CMV, EBV (if acute/icteric presentation) 1
Pattern Recognition
- Hepatocellular pattern: ALT/AST elevation predominates (ALT >AST in most chronic diseases except alcoholic liver disease where AST:ALT ratio typically >2:1)
- Cholestatic pattern: ALP elevation ≥2× ULN suggests biliary obstruction or cholestatic disease 4
- Mixed pattern: Both hepatocellular and cholestatic features
Step 3: Extended Etiological Workup
Based on Initial Results 1, 2
If hepatocellular pattern with negative viral serology:
- Autoimmune markers: ANA, anti-smooth muscle antibody (ASMA), anti-LKM1, immunoglobulins (IgG elevation suggests autoimmune hepatitis)
- Metabolic screening: Fasting glucose/HbA1c, lipid panel
- Iron studies: Ferritin, transferrin saturation, total iron (hemochromatosis screening)
- Ceruloplasmin: If age <40 years (Wilson's disease)
- Alpha-1 antitrypsin level and phenotype: If emphysema or family history
If cholestatic pattern:
- Antimitochondrial antibody (AMA): Primary biliary cholangitis
- Imaging: Abdominal ultrasound or MRCP to exclude biliary obstruction
Important exclusion criteria for clinical trials (reflects severity thresholds) 4:
- ALT or AST >5× ULN or >250 U/L
- Total bilirubin >1.2× ULN (except Gilbert's syndrome)
- INR >1.2
- Platelets <150,000/μL (unless evaluating cirrhotic patients)
Step 4: Imaging Studies
First-Line Imaging 1, 5
Abdominal ultrasound (all patients):
- Excludes biliary obstruction
- Assesses liver morphology (nodular surface suggests cirrhosis)
- Detects hepatic steatosis
- Identifies focal lesions
- Evaluates spleen size, portal vein patency, ascites
Advanced Imaging (Selective Use)
- MRCP: If cholestatic pattern with suspected biliary disease
- CT/MRI: If focal lesions detected, HCC surveillance in cirrhosis
- Doppler ultrasound: If portal/hepatic vein thrombosis suspected
Step 5: Non-Invasive Fibrosis Assessment
Two-Step Sequential Approach 3, 6, 2
Step 1: Calculate FIB-4 Score
- Formula: (Age × AST) / (Platelets × √ALT)
- **FIB-4 <1.3**: Low probability of advanced fibrosis (NPV >90%)
- FIB-4 1.3-2.67: Indeterminate zone → proceed to Step 2
- FIB-4 >2.67: High probability of advanced fibrosis → refer to hepatology
- Note: Use higher cutoff (>1.9-2.0) in patients ≥65 years 3
Step 2: Vibration-Controlled Transient Elastography (VCTE/FibroScan) 6, 2
- <8 kPa: Minimal/no fibrosis
- 8-12 kPa: Significant fibrosis (F2-F3)
- >12-16 kPa: Advanced fibrosis/cirrhosis
- >16 kPa: Definite cirrhosis → refer to hepatology 2
Alternative: Magnetic Resonance Elastography (MRE)
- More accurate than VCTE but less accessible
- Use if VCTE technically inadequate (obesity, ascites)
Other Fibrosis Scores
- NAFLD Fibrosis Score (NFS): Alternative to FIB-4 for NAFLD
- Enhanced Liver Fibrosis (ELF) test: Proprietary serum marker panel
- APRI score: (AST/ULN) × 100 / Platelets
Step 6: Liver Biopsy (Selective Indications)
When to Perform Liver Biopsy 7
Strong indications:
- Diagnostic uncertainty after comprehensive non-invasive workup 7
- Suspected autoimmune hepatitis requiring immunosuppression (confirm before treatment) 1
- Abnormal liver tests of unknown etiology despite thorough investigation 7
- Suspected overlap syndromes (e.g., AIH-PBC overlap) 1
- Drug-induced liver injury vs. autoimmune hepatitis differentiation 1
- Staging for treatment decisions when non-invasive tests indeterminate 7
Relative contraindications:
- INR >1.5 (consider transjugular approach)
- Platelets <50,000/μL
- Ascites (use transjugular route)
- Suspected vascular lesions
Biopsy Technical Requirements 7
- Minimum adequate sample: ≥2-3 cm length, 16-gauge needle, ≥11 complete portal tracts
- Preferred method: Image-guided (ultrasound) percutaneous or transjugular if coagulopathy/ascites
- Histological assessment: Grade (inflammation) and stage (fibrosis) using standardized systems (Metavir, Batts-Ludwig, or IASL for clinical practice; Ishak for research) 7
Step 7: Disease-Specific Diagnostic Algorithms
For Suspected NAFLD/MASLD 3, 8, 9
- Confirm metabolic risk factors (obesity, diabetes, dyslipidemia)
- Exclude alcohol >21/14 drinks/week (men/women)
- Negative viral hepatitis, hemochromatosis, autoimmune markers
- FIB-4 → VCTE sequential testing
- Liver biopsy if: FIB-4 indeterminate + VCTE indeterminate, or need to distinguish NASH from simple steatosis for clinical trial enrollment
For Suspected Autoimmune Hepatitis 1
- Elevated ALT/AST with hypergammaglobulinemia (IgG)
- Positive ANA, ASMA, or anti-LKM1
- Liver biopsy mandatory before starting immunosuppression (unless prohibitive risk)
- Apply simplified AIH scoring criteria (specificity >95%) or 1999 criteria (higher sensitivity)
- Look for interface hepatitis, plasma cell infiltration, rosette formation on histology
For Suspected Alcoholic Liver Disease 5, 2
- Quantify alcohol: AUDIT-C screening, then full AUDIT if positive
- AST:ALT ratio typically >2:1
- Elevated GGT (>100 U/L warrants fibrosis assessment)
- FibroScan if drinking >50/35 units/week (men/women)
- Liver biopsy shows: steatosis, Mallory-Denk bodies, neutrophilic infiltration, perivenular fibrosis
For Suspected Viral Hepatitis
- Hepatitis B: HBsAg positive → HBV DNA quantification, HBeAg/anti-HBe
- Hepatitis C: Anti-HCV positive → HCV RNA confirmation, genotyping
- Fibrosis staging with FIB-4/VCTE to determine treatment urgency
- Liver biopsy rarely needed (treatment indicated regardless in most cases)
Step 8: Referral Criteria to Hepatology 1, 2
Urgent referral (<2 weeks):
- Acute liver failure (encephalopathy + coagulopathy + jaundice) 1
- Acute-on-chronic liver failure
- Suspected variceal bleeding
- New ascites with suspected spontaneous bacterial peritonitis
Routine referral:
- FIB-4 >2.67 or VCTE >16 kPa (advanced fibrosis/cirrhosis) 2
- Confirmed autoimmune hepatitis requiring immunosuppression 1
- Abnormal liver tests with negative extended workup 2
- Chronic viral hepatitis requiring treatment consideration
- Suspected overlap syndrome
- Alcohol dependency (AUDIT >19) with advanced fibrosis 2
Common Pitfalls to Avoid
- Don't assume normal liver tests exclude cirrhosis: Up to 30% of cirrhotic patients have normal ALT 2
- Don't overlook Gilbert's syndrome: Isolated unconjugated hyperbilirubinemia with normal liver enzymes is benign
- Don't miss drug-induced liver injury: Always obtain complete medication/supplement history including recent additions 4, 1
- Don't rely on single FIB-4 or VCTE: Sequential testing improves accuracy and reduces unnecessary referrals 3
- Don't perform liver biopsy without excluding biliary obstruction first: Always image before biopsy 1
- Don't start immunosuppression for presumed AIH without biopsy confirmation: 20-30% of suspected AIH cases have alternative diagnoses 1, 5
- Don't forget to screen for HCC and varices once cirrhosis confirmed: 6-month ultrasound surveillance and endoscopy indicated 7
Quality Indicators for Liver Disease Workup 2
- Percentage of patients with abnormal liver tests receiving extended etiological screen
- Percentage with FIB-4 calculated when indicated
- Percentage with advanced fibrosis (FIB-4 >2.67 or VCTE >16 kPa) referred to hepatology
- Time from abnormal liver test to specialist referral when indicated
- Percentage of cirrhotic patients enrolled in HCC surveillance